Graphite Bio Secures $45M Series A To Advance Targeted Gene Editing Therapy

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

What Happened in Switzerland?
RayzeBio Snags $45M to Reimagine Targeted Radiotherapies for Cancer
Attralus Secures $25M Series A to Diagnose and Treat Amyloidosis
Beyond AAV: AVROBIO and Orchard Take Ex Vivo Approach to Gene Therapy